TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
about
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
TP53 mutations predict for poo ...... ients treated with crizotinib.
@en
TP53 mutations predict for poo ...... ients treated with crizotinib.
@nl
type
label
TP53 mutations predict for poo ...... ients treated with crizotinib.
@en
TP53 mutations predict for poo ...... ients treated with crizotinib.
@nl
prefLabel
TP53 mutations predict for poo ...... ients treated with crizotinib.
@en
TP53 mutations predict for poo ...... ients treated with crizotinib.
@nl
P2093
P2860
P356
P1476
TP53 mutations predict for poo ...... tients treated with crizotinib
@en
P2093
Chun-Wei Xu
Fang-Fang Chen
Jian-Ping Lu
Li-Hua Zhong
Rong-Rong Chen
Tang-Feng Lv
Wei-Feng Zhu
Wen-Xian Wang
P2860
P304
P356
10.21037/JTD.2018.04.98
P577
2018-05-01T00:00:00Z